EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2017, after the market close, and will host a corporate update conference call and webcast on Thursday, May 4th, at 4:30 PM Eastern Time.
Thursday, May 4th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Replays, available through May 18, 2017:
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com